TwinFlo™Catheter to Treat the Ischemic Brain by Providing Rapid, Deep and Selective Cerebral Hypothermia

Problem— Current therapies for ischemic stroke embody recanalization strategies. However, time limitation for lytics excludes most patients, and mechanical revascularization is limited by the location of the occlusion and the small number of trained physicians. Moreover, all current recanalization therapies are subject to reperfusion injury which may impact funtional outcomes. In cardiac arrest, brain death is the major cause of death and disability. Thus, protecting the brain remains to be one of the most important unmet clinical needs today. Therapeutic hypothermia is the most potent neuroprotectant, but in the clinical setting, no device or technique has been able to cool the brain deep enough.

Product— TwinFlo™ is a patented endovascular catheter whose unique design selectively cools the brain rapidly and safely to temperatures science has shown to be most effective, while maintaining the remainder of the body at normal temperature (selective hypothermia). The design also permits selective drug and/or device delivery concurrent with the hypothermia treatment. Use of the catheter will be familiar to the large number of interventional physicians on staff at most hospitals, which will provide expanded access to patients.

Medical Significance and Markets— Neuroprotection provided by TwinFlo™ addresses most of the limitations of current and near-term therapies for acute stroke and cardiac arrest. By increasing patient access to timely treatment and improving their outcomes, TwinFlo™ will also provide significant economic and social benefits to payers, providers, caregivers, and employers. A key market driver is the interest and ability of interventional physicians, especially interventional cardiologists and radiologists, to adopt the product and expand their practice. The tremendous market need for an efficacious therapy for neuroprotection translates to potential annual revenues exceeding $3 billion.

Team— The founders each have 40+ years MedTech experience including multiple successful startup exits and key leadership/development roles for many strategics.

Link to Video— https://www.youtube.com/watch?v=XGkt3gSozo4